The approval of the COVID-19 mRNA vaccines brought much optimism to efforts to end the pandemic . A recombinant adenovirus vaccine recently received emergency use authorization and several other vaccines likely to follow . These vaccines all utilize relatively new vaccine production platforms to produce the SARS-CoV2 Spike protein . This review discusses how these platforms work, what advantages they offer and the gaps that remain in public health efforts to control the COVID-19 pandemic.